PL4041748T3 - Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1 - Google Patents
Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1Info
- Publication number
- PL4041748T3 PL4041748T3 PL20780745.4T PL20780745T PL4041748T3 PL 4041748 T3 PL4041748 T3 PL 4041748T3 PL 20780745 T PL20780745 T PL 20780745T PL 4041748 T3 PL4041748 T3 PL 4041748T3
- Authority
- PL
- Poland
- Prior art keywords
- agonists
- side effects
- peptide compounds
- reducing side
- reducing
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382856.3A EP3800195A1 (en) | 2019-10-03 | 2019-10-03 | Peptide compounds for reducing side effects of cb1 receptor agonists |
| PCT/EP2020/077642 WO2021064165A1 (en) | 2019-10-03 | 2020-10-02 | Peptide compounds for reducing side effects of cb1 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4041748T3 true PL4041748T3 (pl) | 2024-10-21 |
Family
ID=68281384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20780745.4T PL4041748T3 (pl) | 2019-10-03 | 2020-10-02 | Związki peptydowe do redukowania skutków ubocznych agonistów receptorów cb1 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12459973B2 (pl) |
| EP (2) | EP3800195A1 (pl) |
| JP (1) | JP7781422B2 (pl) |
| CN (1) | CN114641486B (pl) |
| AU (1) | AU2020360716B2 (pl) |
| CA (1) | CA3156280A1 (pl) |
| ES (1) | ES2984754T3 (pl) |
| PL (1) | PL4041748T3 (pl) |
| WO (1) | WO2021064165A1 (pl) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7410949B2 (en) * | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| DK2878306T3 (en) * | 2012-07-13 | 2019-03-04 | Proteimax Biotecnologia Ltda | MODIFIED PEPTIDE, CB RECEPTOR LIGAND, KIT, IN VITRO PROCEDURE FOR EVALUATION OF CB RECEPTOR BINDINGS, APPLICATIONS, PHARMACEUTICAL COMPOSITION FOR MODULATING CBRECEPTOR ACTIVITY |
| US9656981B2 (en) * | 2012-07-20 | 2017-05-23 | The Regents Of The University Of California | Peripherally-acting cannabinoid receptor agonists for chronic pain |
| SG11201705986QA (en) | 2015-01-29 | 2017-08-30 | Technophage Investigação E Desenvolvimento Em Biotecnologia Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
-
2019
- 2019-10-03 EP EP19382856.3A patent/EP3800195A1/en not_active Withdrawn
-
2020
- 2020-10-02 PL PL20780745.4T patent/PL4041748T3/pl unknown
- 2020-10-02 US US17/766,355 patent/US12459973B2/en active Active
- 2020-10-02 CN CN202080069052.8A patent/CN114641486B/zh active Active
- 2020-10-02 EP EP20780745.4A patent/EP4041748B1/en active Active
- 2020-10-02 CA CA3156280A patent/CA3156280A1/en active Pending
- 2020-10-02 WO PCT/EP2020/077642 patent/WO2021064165A1/en not_active Ceased
- 2020-10-02 AU AU2020360716A patent/AU2020360716B2/en active Active
- 2020-10-02 ES ES20780745T patent/ES2984754T3/es active Active
- 2020-10-02 JP JP2022520668A patent/JP7781422B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023504765A (ja) | 2023-02-07 |
| ES2984754T3 (es) | 2024-10-30 |
| EP4041748C0 (en) | 2024-05-01 |
| US20240059737A1 (en) | 2024-02-22 |
| CA3156280A1 (en) | 2021-04-08 |
| US12459973B2 (en) | 2025-11-04 |
| AU2020360716A1 (en) | 2022-04-21 |
| AU2020360716B2 (en) | 2025-09-04 |
| EP4041748B1 (en) | 2024-05-01 |
| CN114641486A (zh) | 2022-06-17 |
| EP4041748A1 (en) | 2022-08-17 |
| CN114641486B (zh) | 2025-04-01 |
| WO2021064165A1 (en) | 2021-04-08 |
| JP7781422B2 (ja) | 2025-12-08 |
| EP3800195A1 (en) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| IL289534A (en) | Parp1 inhibitors | |
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| EP4007752C0 (en) | Kif18a inhibitors | |
| EP3843714A4 (en) | CD73 INHIBITORS | |
| EP4007753C0 (en) | Kif18a inhibitors | |
| EP3652329A4 (en) | COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| IL262180A (en) | Compositions for topical application of compounds | |
| IL304348A (en) | Cd73 inhibitors | |
| IL283385A (en) | Modified gip peptide analogues | |
| EP3423451A4 (en) | INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING | |
| MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
| EP3999517A4 (en) | CD73 INHIBITORS | |
| IL308293B2 (en) | Cd73 inhibitors | |
| EP3364337C0 (en) | PERSISTENT FEATURE DESCRIPTORS FOR VIDEO | |
| SG11202101613XA (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| LT3980417T (lt) | Prmt5 inhibitoriai | |
| EP3679031A4 (en) | INHIBITORS OF WDR5 PROTEIN PROTEIN BINDING | |
| EP3980011A4 (en) | INHIBITORS OF SARM1 | |
| IL290878A (en) | Protein based cannabis compositions | |
| EP3884940A4 (en) | Novel imidazole derivative | |
| EP3761962A4 (en) | EXCIPIENT COMPOUNDS FOR PROTEIN-BASED FORMULATIONS | |
| IL280047A (en) | Formulation of cannabinoid compounds | |
| EP4257597A4 (en) | LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS |